Clinical Snippets

The incomplete understanding of the pathogenesis of the chronic inflammatory disease hidradenitis suppurativa (HS) contributes to a lack of effective therapies. Recently, a proof-of-concept phase 2 clinical trial showed that fostamatinib, a spleen Y kinase inhibitor, led to clinical benefit in patients with moderate-to-severe HS. Proteomics analysis of samples from the study demonstrated that inhibition with fostamatinib downregulated T helper 17 –associated cytokines IL-12B and IL-17A; B-cell–associated chemokines CCL19 and CCL20; and IFN-γ–associated proteins CX3CL1, IL-2, and CXCL10 in the serum of patients with HS.
Source: Journal of Investigative Dermatology - Category: Dermatology Tags: Clinical Snippets Source Type: research